Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 5
2008 3
2009 4
2010 4
2011 5
2012 10
2013 13
2014 10
2015 20
2016 27
2017 14
2018 20
2019 31
2020 31
2021 44
2022 59
2023 46
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis.
He J, Chu Y, Li J, Meng Q, Liu Y, Jin J, Wang Y, Wang J, Huang B, Shi L, Shi X, Tian J, Zhufeng Y, Feng R, Xiao W, Gan Y, Guo J, Shao C, Su Y, Hu F, Sun X, Yu J, Kang Y, Li Z. He J, et al. Among authors: sun x. Sci Adv. 2022 Feb 11;8(6):eabm1511. doi: 10.1126/sciadv.abm1511. Epub 2022 Feb 11. Sci Adv. 2022. PMID: 35148177 Free article.
Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial.
He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, Jin Y, Zhang X, Shao M, Wang Y, Zhang X, Li J, Zhao X, Wang H, Liu T, Xiao X, Zhang X, Su Y, Mu R, Ye H, Li R, Liu X, Liu Y, Li C, Liu H, Hu F, Guo J, Liu W, Zhang WB, Jacob A, Ambrus JL Jr, Ding C, Yu D, Sun X, Li Z. He J, et al. Among authors: sun x. JAMA Netw Open. 2022 Nov 1;5(11):e2241451. doi: 10.1001/jamanetworkopen.2022.41451. JAMA Netw Open. 2022. PMID: 36355371 Free PMC article. Clinical Trial.
Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
He J, Zhang X, Wei Y, Sun X, Chen Y, Deng J, Jin Y, Gan Y, Hu X, Jia R, Xu C, Hou Z, Leong YA, Zhu L, Feng J, An Y, Jia Y, Li C, Liu X, Ye H, Ren L, Li R, Yao H, Li Y, Chen S, Zhang X, Su Y, Guo J, Shen N, Morand EF, Yu D, Li Z. He J, et al. Among authors: sun x. Nat Med. 2016 Sep;22(9):991-3. doi: 10.1038/nm.4148. Epub 2016 Aug 8. Nat Med. 2016. PMID: 27500725
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.
He J, Zhang R, Shao M, Zhao X, Miao M, Chen J, Liu J, Zhang X, Zhang X, Jin Y, Wang Y, Zhang S, Zhu L, Jacob A, Jia R, You X, Li X, Li C, Zhou Y, Yang Y, Ye H, Liu Y, Su Y, Shen N, Alexander J, Guo J, Ambrus J, Lin X, Yu D, Sun X, Li Z. He J, et al. Among authors: sun x. Ann Rheum Dis. 2020 Jan;79(1):141-149. doi: 10.1136/annrheumdis-2019-215396. Epub 2019 Sep 19. Ann Rheum Dis. 2020. PMID: 31537547 Free PMC article. Clinical Trial.
320 results